Emerging Technologies and Computation Methods for Precision Medicine in Cancer—Ready for Use in Clinics?

Guest Editor:

Dr. Maggie Chon U Cheang
The Institute of Cancer Research, Division of Clinical Studies, Clinical Trials and Statistics Unit (ICR-CTSU), 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK

Deadline for manuscript submissions:
closed (30 September 2021)

Message from the Guest Editor

Dear Colleagues,

The theme is on clinical cancer genomics. The advent of cancer genomics technologies is providing increasingly more hope to improve cancer patient outcomes and the potential to reduce healthcare costs and adverse drug reactions. The role of biomarkers in cancer clinical trials has significantly increased in recent years, and availability and decreasing costs of high-throughput technologies has vastly increased the amount of molecular data derived from biospecimens collected in trials. In this Special Issue, we invite cancer researchers to submit original research articles, reviews or short communications that apply or develop emerging genomic technologies and computational methods for biomarker research that can be applied in clinical studies, and translational studies whose results are making real impact for clinical practice in cancer.

Dr. Maggie Chon U Cheang
Guest Editor

mdpi.com/si/51370

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us